This site is intended for healthcare professionals

Xenon Pharmaceuticals receives FDA feedback and plans to initiate XEN 496 phase III clinical trial for the treatment of KCNQ2-DEE before year-end.

Read time: 1 mins
Last updated:12th Oct 2020
Published:12th Oct 2020
Condition: KCNQ2 epileptic encephalopathy
Type: drug
Register free for full access to